

## Santhera Provides Update on the Share Placement

**Pratteln, Switzerland, December 14, 2018 – Santhera Pharmaceuticals Holding AG (SIX: SANN) provides an update on the accelerated bookbuilding.**

On December 12, 2018, Santhera Pharmaceuticals Holding AG announced the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to be offered through an accelerated bookbuilding.

Based on the current status of the book, the share placement would amount to 3,133,334 new shares to be priced at CHF 7.50 per share, which would result in CHF 23.5 million gross proceeds. On this basis, the Company expects the placement to proceed as planned. The offer period will expire today, December 14, 2018, at 09:00 a.m. (CET).

The final number of offered shares, the final offer price, the final gross proceeds, and the Company's share capital following consummation of the capital increase will be set out in a separate press release to be published over the course of today following the expiry of the offer period.

As set out in the announcement published at launch of the share placement, the Company intends to use the CHF equivalent of USD 20 million of the net proceeds to pay the cash component of the consideration to Idorsia for the acquisition of the option for the exclusive sub-license relating to ReveraGen's vamorolone.

Subject to certain customary exceptions, the Company has agreed that, during the period ending 90 days after the first day of trading of the new shares, the Company shall not issue or sell any Santhera shares or securities convertible into or exchangeable or exercisable for Santhera shares or warrants or other rights to purchase Santhera shares.

The Company expects that the offered shares will be listed and admitted to trading on the SIX Swiss Exchange according to its International Reporting Standard on or around December 18, 2018. Payment and settlement is expected to take place on or around December 18, 2018.

To download the complete press release, follow this link: <http://www.santhera.com/investors-and-media/investor-toolbox/capital-increase> (country and other restrictions may apply).

### **About Santhera**

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. The portfolio comprises clinical stage and marketed treatments for neuro-ophthalmologic, neuromuscular and pulmonary diseases. Santhera's Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. For further information, please visit [www.santhera.com](http://www.santhera.com).

*Raxone® is a trademark of Santhera Pharmaceuticals.*

**For further information please contact:**

[public-relations@santhera.com](mailto:public-relations@santhera.com) or

Eva Kalias, Head External Communications

Phone: +41 78 671 98 86

[eva.kalias@santhera.com](mailto:eva.kalias@santhera.com)

**For Investors:**

[investor-relations@santhera.com](mailto:investor-relations@santhera.com) or

Christoph Rentsch, Chief Financial Officer

Europe: +41 61 906 89 65

[christoph.rentsch@santhera.com](mailto:christoph.rentsch@santhera.com)

Hans Vitzthum, LifeSci Advisors

US: +1 212 915 2568

[hans@lifesciadvisors.com](mailto:hans@lifesciadvisors.com)

**Disclaimer / Forward-looking statements**

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This communication is not an issue prospectus within the meaning of art. 652a of the Swiss Code of Obligations and not a listing prospectus within the meaning of art. 27 et seq. of the Listing Rules of SIX Swiss Exchange and has been prepared without regard to the requirements thereof. Investors should make any decision to buy shares of Santhera Pharmaceuticals Holding AG solely based on the offering memorandum dated as of December 12, 2018 issued by Santhera Pharmaceuticals Holding AG. Investors are furthermore advised to consult their bank, broker or financial adviser before making any investment decision. This publication may contain certain forward-looking statements relating to the Company and/or its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update any such forward-looking statements.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The securities of Santhera Pharmaceuticals Holding AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States.

###